Compare Bank of Montreal (BMO) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bank of Montreal vs Sana Biotechnology Inc — how do they compare? Bank of Montreal trades at $183.11 (market cap $126.83B), while Sana Biotechnology Inc trades at $3.77 (market cap $1.13B). The key difference: Bank of Montreal is far larger — about 112.2× Sana Biotechnology Inc's market cap, and Bank of Montreal pays a 2.69% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| BMO | SANA | |
|---|---|---|
Market Cap | $126.83B | $1.13B |
Sector | Financials | Health |
52-Week High | $183.65 | $5.92 |
52-Week Low | $112.54 | $2.68 |
Dividend Yield | 2.69% | — |
Enterprise Value | — | $1.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BMO trades at $181.91, up 0.2% today, with a bullish technical signal from moving averages and support near $181. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $2.68 exceeding the $2.54 estimate. Revenue grew to $36.10B in 2025, and net income margin improved to 24.12%. Recent news includes the sale of Moneris for $1.44B and the launch of new ETNs with REX Shares.
Outlook is supported by consistent earnings performance and strategic initiatives, but risks include interest rate sensitivity and macroeconomic pressures. Analysts are divided with a Hold consensus, reflecting balanced optimism and caution. The stock's valuation at a P/E of 19.41 appears reasonable given profitability trends.
SANA Biotechnology trades at $3.775, up 4.57% with strong technical momentum as moving averages signal bullish sentiment. The company shows significant financial challenges with negative ROE (-152.87%) and net income (-$244.17M in 2025), though recent analyst upgrades and clinical developments in cell therapy research provide optimism. Cash flow remains negative but improved from -$55M to -$14M year-over-year, while the stock benefits from 82% buy ratings from analysts.
Investment outlook balances high-risk fundamentals against promising biotechnology breakthroughs. The primary opportunity lies in successful clinical trial outcomes and market adoption of engineered cell therapies, while risks include sustained cash burn, execution challenges, and competitive pressures in the genomics space. Wall Street's $9.50 price target suggests substantial upside potential if operational improvements materialize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bank of Montreal
Bank of Montreal is a diversified financial-services provider based in North America, operating four business segments: Canadian personal and commercial banking, U.S. P&C banking, wealth management, and capital markets. The bank's operations are primarily in Canada, with a material portion also in the U.S.
Read more on BMO →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
